What happens if IVDA’s share price stays below $1 through September 2, 2026?

If Iveda Solutions does not regain compliance by September 2, 2026, or violates other listing standards, Nasdaq may determine that its securities are subject to delisting. In that event, Iveda would be permitted under Nasdaq rules to appeal the delisting decision to a Nasdaq Hearings Panel.

Iveda warned by Nasdaq over sub-$1 share price

Iveda Solutions, Inc. has been notified by Nasdaq that its common stock no longer meets the exchange’s minimum bid price requirement of $1 per share, after trading below that level for 30 consecutive business days.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Iveda Solutions, Inc. has been notified by Nasdaq that its common stock no longer meets the exchange’s minimum bid price requirement of $1 per share, after trading below that level for 30 consecutive business days. The notice does not immediately affect the stock’s Nasdaq listing.

The company has 180 calendar days, until September 2, 2026, to regain compliance. Nasdaq will deem the requirement met if the closing bid price is at least $1 for a minimum of ten consecutive business days during this period. If compliance is not restored or other listing rules are breached, Nasdaq may move to delist the shares, although Iveda could appeal any delisting determination to a Nasdaq Hearings Panel.

Positive

None.

Negative

Nasdaq minimum bid price deficiency increases the risk of eventual delisting if Iveda Solutions, Inc. cannot lift and sustain its share price to at least $1 for ten consecutive business days within the 180-day compliance window ending September 2, 2026.

Insights

Nasdaq bid-price noncompliance creates delisting risk but with a defined cure window.

Iveda Solutions has fallen out of compliance with Nasdaq’s $1 minimum bid price rule after 30 consecutive business days below that threshold. This triggers a formal deficiency period but leaves the current listing intact for now.

The company has until September 2, 2026 to regain compliance by maintaining a closing bid of at least $1 for ten consecutive business days. Failure to do so allows Nasdaq to start delisting proceedings, though Iveda would be able to request a hearing before a Nasdaq Hearings Panel, as described in the notice.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq issue did Iveda Solutions (IVDA) disclose on March 6, 2026?

Iveda Solutions disclosed receiving a Nasdaq notice that its common stock failed to maintain the required minimum bid price of $1 per share for 30 consecutive business days, placing the company out of compliance with Nasdaq Listing Rule 5550(a)(2) and starting a formal cure period.

Does the Nasdaq deficiency notice immediately affect IVDA’s stock listing?

The Nasdaq notice has no immediate effect on Iveda Solutions’ Nasdaq listing. The company’s common stock continues trading while it works to regain compliance with the $1 minimum bid price requirement during the specified 180-day grace period described in the notice.

How long does Iveda Solutions (IVDA) have to regain Nasdaq bid price compliance?

Iveda Solutions has 180 calendar days, until September 2, 2026, to regain compliance. The company must achieve a closing bid price of at least $1 per share for a minimum of ten consecutive business days within this period for Nasdaq to confirm compliance.

What specific Nasdaq rules are involved in Iveda Solutions’ (IVDA) deficiency notice?

The situation involves Nasdaq Listing Rule 5550(a)(2), which sets the $1 minimum bid price, and Rule 5810(c)(3)(A), which grants a 180-day compliance period. The company reported the notice under Nasdaq Listing Rule 5810(b), which requires public disclosure of such deficiency communications.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/06/2026 - 04:30 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

March 6, 2026

Date of Report (Date of earliest event reported)

IVEDA SOLUTIONS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-41345	20-2222203
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

1744 S. Val Vista, Suite 213

Mesa, Arizona

85204

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (480) 307-8700

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.00001	IVDA	The Nasdaq Stock Market LLC
Common Stock Purchase Warrants	IVDAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On March 6, 2026, Iveda Solutions, Inc., a Delaware corporation (the “Company”), received a letter (the “Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company’s common stock failed to maintain a minimum bid price of $1 per share, based upon the closing bid price for the last 30 consecutive business days. Accordingly, the Company failed to comply with Rule 5550(a)(2) the Nasdaq Listing Rules (the “Rules”).

The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. Rule 5810(c)(3)(A) provides the Company a compliance period of 180 calendar days, or until September 2, 2026, in which to regain compliance. If at any time during this 180 day period the closing bid price of the Company’s common stock is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance with the Rules and this matter will be closed.

If the Company does not regain compliance within the compliance period, or if the Company fails to satisfy another Nasdaq requirement for continued listing, Nasdaq could provide notice that the Company’s securities will become subject to delisting. In such event, Nasdaq rules would permit the Company to appeal the decision to reject any delisting determination to a Nasdaq Hearings Panel.

The Company, by filing this Form 8-K, discloses its receipt of the Letter in accordance with Nasdaq Listing Rule 5810(b).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 6, 2026

	IVEDA SOLUTIONS, INC.

	By:	/s/ Robert J. Brilon
	Name:	Robert J. Brilon
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Iveda warned by Nasdaq over sub-$1 share price